Invesco Ltd. Phathom Pharmaceuticals, Inc. Transaction History
Invesco Ltd.
- $503 Billion
- Q1 2025
A detailed history of Invesco Ltd. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 3,650,812 shares of PHAT stock, worth $14.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,650,812
Previous 3,671,386
0.56%
Holding current value
$14.3 Million
Previous $29.8 Million
23.22%
% of portfolio
0.0%
Previous 0.01%
Shares
22 transactions
Others Institutions Holding PHAT
# of Institutions
152Shares Held
66.6MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$39.5 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$29.2 Million12.73% of portfolio
-
Jennison Associates LLC7.04MShares$27.5 Million0.03% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$13.7 Million27.15% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$11.4 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $153M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...